The Challenge
Critical MSI testing omitted from NGS report, limiting trial eligibility.
Our Impact
Cancer Commons identified the testing gap (missed by her oncologist), advocated for repeat testing, and identified high-priority KRAS G13D trials with detailed enrollment pathways.
The Outcome
Expanded his clinical trial options and clarified his treatment strategy through complete biomarker profiling.
